# Detection of Left Ventricular Systolic Dysfunction from Electrocardiographic Images

Veer Sangha[1*], Arash A Nargesi MD, MPH[2,3*], Lovedeep S Dhingra MBBS[3], Akshay Khunte[1],

Bobak J Mortazavi PhD[4,5], Antônio H Ribeiro PhD[6], Evgeniya Banina MD[7], Oluwaseun Adeola

MD, MPH[8], Nadish Garg MD[9], Cynthia A Brandt MD, MPH[10,11], Edward J Miller MD, PhD[3],

Antonio Luiz J Ribeiro MD, PhD[12,13], Eric J Velazquez MD, PhD[3], Luana Giatti MD, PhD[14],

Sandhi M Barreto MD, PhD[15], Murilo Foppa MD, PhD[16], Neal Yuan MD[17,18], David Ouyang

MD[19,20], Harlan M Krumholz MD, SM[5,3,21], Rohan Khera MD, MS[3,5,22]

[1]Department of Computer Science, Yale University, New Haven, CT, USA

[2]Heart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston,

MA, USA

[3]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New

Haven, CT, USA

[4]Department of Computer Science & Engineering, Texas A&M University, College Station, TX,

USA

[5]Center for Outcomes Research and Evaluation (CORE), Yale New Haven Hospital, New

Haven, CT, USA

[6]Department of Information Technology, Uppsala University, Uppsala, Sweden

[7]Internal Medicine Department, Lake Regional Hospital Health, Osage Beach, MO, USA

[8]Methodist Cardiology Clinic of San Antonio, San Antonio, TX, USA

[9]Heart and Vascular Institute, Memorial Hermann Southeast Hospital, Houston, TX, USA

[10]Department of Emergency Medicine, Yale University, New Haven, CT, USA

[11]VA Connecticut Healthcare System, West Haven, CT, USA

[12]Telehealth Center and Cardiology Service, Hospital das Clínicas, Universidade Federal de

Minas Gerais, Belo Horizonte, Brazil

[13]Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas

Gerais, Belo Horizonte, Brazil

[14]Department of Preventive Medicine, School of Medicine and Hospital das Clínicas,

Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

[15]Department of Preventive Medicine, School of Medicine, and Hospital das Clínicas,

Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

[16]Postgraduate Studies Program in Cardiology and Division of Cardiology, Hospital de Clinicas

de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

[17]Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

[18]Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA,

USA

[19]Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles,

CA, USA

[20]Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,

USA

[21]Department of Health Policy and Management, Yale School of Public Health, New Haven, CT,

USA

[22]Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New

Haven, CT, USA

*Contributed equally

**Correspondence to:** Rohan Khera, MD, MS

195 Church St, 5<sup>th</sup> Floor, New Haven, CT 06510, 203-764-5885; rohan.khera@yale.edu;

@rohan_khera

**ABSTRACT**

**Background**: Left ventricular (LV) systolic dysfunction is associated with over 8-fold increased risk of heart failure and a 2-fold risk of premature death. The use of electrocardiogram (ECG) signals in screening for LV systolic dysfunction is limited by their availability to clinicians. We developed a novel deep learning-based approach that can use ECG images for the screening of LV systolic dysfunction.

**Methods**: Using 12-lead ECGs plotted in multiple different formats, and corresponding echocardiographic data recorded within 15 days from the Yale-New Haven Hospital (YNHH) during 2015-2021, we developed a convolutional neural network algorithm to detect LV ejection fraction $< 40\%$. The model was validated within clinical settings at YNHH as well as externally on ECG images from Cedars Sinai Medical Center in Los Angeles, CA, Lake Regional Hospital (LRH) in Osage Beach, MO, Memorial Hermann Southeast Hospital in Houston, TX, and Methodist Cardiology Clinic of San Antonia, TX. In addition, it was validated in the prospective Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Gradient-weighted class activation mapping was used to localize class-discriminating signals in ECG images.

**Results**: Overall, 385,601 ECGs with paired echocardiograms were used for model development. The model demonstrated high discrimination power across various ECG image formats and calibrations in internal validation (area under receiving operation characteristics [AUROC] 0.91, area under precision-recall curve [AUPRC] 0.55), and external sets of ECG images from Cedars Sinai (AUROC 90, AUPRC 0.53), outpatient YNHH clinics (AUROC 0.94, AUPRC 0.77), LRH (AUROC 0.90, AUPRC 0.88), Memorial Hermann Southeast Hospital (AUROC 0.91, AUPRC 0.88), Methodist Cardiology Clinic (AUROC 0.90, AUPRC 0.74), and ELSA-Brasil cohort (AUROC 0.95, AUPRC 0.45). An ECG suggestive of LV systolic dysfunction portended over 27-fold higher odds of LV systolic dysfunction on TTE (OR 27.5, 95% CI, 22.3-33.9 in the held-

out set). Class-discriminative patterns localized to the anterior and anteroseptal leads (V2-V3),

corresponding to the left ventricle regardless of the ECG layout. A positive ECG screen in

individuals with LV ejection fraction ≥ 40% at the time of initial assessment was associated with

a 3.9-fold increased risk of developing incident LV systolic dysfunction in the future (HR 3.9,

95% CI 3.3-4.7, median follow-up 3.2 years).

**Conclusions**: We developed and externally validated a deep learning model that identifies LV

systolic dysfunction from ECG images. This approach represents an automated and accessible

screening strategy for LV systolic dysfunction, particularly in low-resource settings.

**ABBREVIATIONS AND ACRONYMS**

| | | |
|---|---|---|
| 86 | LV | Left ventricle |
| 87 | ECG | Electrocardiography |
| 88 | AI | Artificial Intelligence |
| 89 | LVEF | Left ventricular ejection fraction |
| 90 | YNHH | Yale New Haven Hospital |
| 91 | TTE | Transthoracic echocardiography |
| 92 | LRH | Lake Regional Hospital |
| 93 | ELSA-Brasil | ELSA-Brasil, Estudo Longitudinal de Saúde do Adulto |
| 94 | | (The Brazilian Longitudinal Study of Adult Health) |
| 95 | Grad-CAM | Gradient-weighted Class Activation Mapping |
| 96 | AUROC | Area under receiving operation characteristics |
| 97 | AUPRC | Area under precision recall curve |

**CLINICAL PERSPECTIVE**

**What is New?**

- A convolutional neural network model that accurately identifies LV systolic dysfunction

from ECG images across subgroups of age, sex, and race.

- The model shows robust performance across multiple institutions and health settings,

both applied to ECG image databases as well as directly uploaded single ECG images to

a web-based application by clinicians.

- The approach provides information for both screening of LV systolic dysfunction and its

risk based on ECG images alone.

**What are the clinical implications?**

- Our model represents an automated screening strategy for LV systolic dysfunction on a

variety of ECG layouts.

- With availability of ECG images in practice, this approach overcomes implementation

challenges of deploying an interoperable screening tool for LV systolic dysfunction in

resource-limited settings.

- This model is available in an online format to facilitate real-time screening for LV

systolic dysfunction by clinicians.

## INTRODUCTION

Left ventricular (LV) systolic dysfunction is associated with over 8-fold increased risk of subsequent heart failure and nearly 2-fold risk of premature death.[1] While early diagnosis can effectively lower this risk,[2–4] individuals are often diagnosed after developing symptomatic disease due to lack of effective screening strategies.[5–7] The diagnosis traditionally relies on echocardiography, a specialized imaging modality that is resource intensive to deploy at scale.[8,9] Algorithms using raw signals from electrocardiography (ECG) have been developed as a strategy to detect LV systolic dysfunction.[10–12] However, clinicians, particularly in remote settings, do not have access to ECG signals. The lack of interoperability in signal storage formats from ECG devices further limits the broad uptake of such signal-based models.[13] The use of ECG images is an opportunity to implement interoperable screening strategies for LV systolic dysfunction.

We previously developed a deep learning approach of format-independent inference from real-world ECG images.[14] The approach can interpretably diagnose cardiac conduction and rhythm disorders using any layout of real-world 12-lead ECG images and can be accessed on web- or application-based platforms. Extension of this artificial intelligence (AI)-driven approach to ECG images to screen for LV systolic dysfunction could rapidly broaden access to a low cost, easily accessible, and scalable diagnostic approach to underdiagnosed and undertreated at-risk populations. This approach adapts deep learning for end-users, without disruption of data pipelines or clinical workflow. Moreover, the ability to add localization of predictive cues in the ECG images relevant to the LV can improve the uptake of these models in clinical practice.[15]

In this study, we present a model for accurate identification of LV ejection fraction (LVEF) less than 40%, a threshold with therapeutic implications, based on ECG images. We

developed, tested, and externally validated this approach using paired ECG-echocardiographic

data from large academic hospitals, rural hospital systems, and a prospective cohort study.

**METHODS**

The Yale Institutional Review Board reviewed the study, which approved the study protocol and

waived the need for informed consent as the study represents a secondary analysis of existing

data. The data cannot be shared publicly though an online version of the model is publicly

available for research use at https://www.cards-lab.org/ecgvision-lv.

**Data Source for Model Development**

We used 12-lead ECG signal waveform data from the Yale New Haven Hospital (YNHH)

collected between 2015 and 2021. These ECGs were recorded as standard 12-lead recordings

sampled at a frequency of 500 Hz for 10 seconds. These were recorded on multiple different

machines and a majority were collected using Philips PageWriter machines and GE MAC

machines. Among patients with an ECG, those with a corresponding transthoracic

echocardiogram (TTE) within 15 days of obtaining the ECG were identified from the YNHH

electronic health records. LVEF values were extracted based on a cardiologist's read of the

nearest TTE to each ECG. To augment the evaluation of models built on an image dataset

generated from this YNHH signal waveform, six sets of ECG image datasets were used for

external validation.

**Data Preprocessing**

All ECGs were analyzed to determine whether they had 10 seconds of continuous recordings

across all 12 leads. The 10 second samples were preprocessed with a one second median filter,

which was subtracted from the original waveform to remove baseline drift in each lead,

representing processing steps pursued by ECG machines before generating printed output from

collected waveform data.

162             ECG signals were transformed into ECG images using the python library ecg-plot,[16] and

stored at 100 DPI. Images were generated with a calibration of 10 mm/mV, which is standard for

printed ECGs in most real-world settings. In sensitivity analyses, we evaluated model

performance on images calibrated at 5 and 20 mm/mV. All images, including those in train,

validation, and test sets, were converted to greyscale, followed by down-sampling to 300x300

pixels regardless of their original resolution using Python Image Library (PIL v9.2.0). To ensure

that the model was adaptable to real-world images, which may vary in formats and the layout of

leads, we created a dataset with different plotting schemes for each signal waveform recording

(**Figure 1**). This strategy has been used to train a format-independent image-based model for

detecting conduction and rhythm disorders as well as the hidden label of gender.[14] The model in

this study learned ECG lead-specific information based on the label regardless of the location of

the lead.

174             Four formats of images were included in the training image dataset (**Figure 1**). The first

format was based on the standard printed ECG format in the United States, with four 2.5 second

columns printed sequentially on the page. Each column contained 2.5 second intervals from three

leads. The full 10-second recording of the lead I signal was included as the rhythm strip. The

second format, a two-rhythm format, added lead II as an additional rhythm strip to the standard

format. The third layout was the alternate format which consisted of two columns, the first with

six simultaneous 5-second recordings from the limb leads, and the second with six simultaneous

5-second recordings from the precordial leads, without a corresponding rhythm lead. The fourth

format was a shuffled format, which had precordial leads in the first two columns and limb leads

in the third and fourth. All images were rotated a random amount between -10 and 10 degrees

before being input into the model to mimic variations seen in uploaded ECGs and to aid in

prevention of overfitting.

The process of converting ECG signals to images was independent of model

development, ensuring that the model did not learn any aspects of the processing that generated

images from the signals. All ECGs were converted to images in all different formats without

conditioning on clinical labels. The validation required uploaded images to be upright, cropped

to the waveform region, with no brightness and contrast consideration as long as the waveform is

distinguishable from the background and lead labels are discernible.

**Experimental Design**

Each included ECG had a corresponding LVEF value from its nearest TTE within 15 days of

recording. Low LVEF was defined as LVEF < 40%, the cutoff used as an indication for most

guideline-directed pharmacotherapy for heart failure.[4] Patients with at least one ECG within 15

days of its nearest TTE were randomly split into training, validation, and held-out test patient

level sets (85%, 5%, 10%, **Figure S1**). This sampling was stratified by whether a patient had

ever had LVEF < 40% to ensure cases of preserved and reduced LVEF were split proportionally

among the sets. In the training cohort, all ECGs within 15 days of a TTE were included for all

patients to maximize the data available. In validation and testing cohorts, only one ECG was

included per patient to ensure independence of observations in the assessment of performance

metrics. This ECG was randomly chosen amongst all ECGs within 15 days of a TTE.

Additionally, to ensure that model learning was not affected by the relatively lower frequency of

LVEF < 40%, higher weights were given to these cases at the training stage based on the

effective number of samples class sampling scheme.[17]

**Model Training**

We built a convolutional neural network model based on the EfficientNet-B3 architecture,[18] which previously demonstrated an ability to learn and identify both rhythm and conduction disorders, as well as the hidden label of gender in real-world ECG images.[14] The EfficientNet-B3 model requires images to be sampled at 300 x 300 square pixels, includes 384 layers, and has over 10 million trainable parameters (**Figure S2**). We utilized transfer learning by initializing model weights as the pretrained EfficientNet-B3 weights used to predict the six physician-defined clinical labels and gender from Sangha et al.[14] We first only unfroze the last four layers and trained the model with a learning rate of 0.01 for 2 epochs, and then unfroze all layers and trained with a learning rate of $5 \times 10^{-6}$ for 6 epochs. We used an Adam optimizer, gradient clipping, and a minibatch size of 64 throughout training. The optimizer and learning rates were chosen after hyperparameter optimization. For both stages of training the model, we stopped training when validation loss did not improve in 3 consecutive epochs.

We trained and validated our model on a generated image dataset that had equal numbers of standard, two-rhythm, alternate, and standard shuffled images (**Figure 1**). In sensitivity analyses, the model was validated on three novel ECG layouts constructed from the held-out set to assess its performance on ECG formats not encountered in the training process. These novel ECG outlines included three-rhythm (with leads I, II, and V1 as the rhythm strip), no rhythm, and rhythm on top formats (with lead I as the rhythm strip located above the 12-lead, **Figure S3**). Additional sensitivity analyses were performed using ECG images calibrated at 5, 10, and 20 mm/mV (**Figure S4**). A custom class-balanced loss function (weighted binary cross-entropy) based on the effective number of samples was used given the lower frequency of the LVEF < 40% label relative to those with an LVEF ≥ 40%.

**External validation**

We pursued a series of validation studies. These represented both clinical and population-based cohort studies. Clinical validation represented non-synthetic image datasets from clinical settings spanning (1) consecutive patients undergoing outpatient echocardiography at the Cedars Sinai Medical Center in Los Angeles, CA, and (2) stratified convenience samples of LV systolic dysfunction and non-LV systolic dysfunction ECGs from four different settings (a) outpatient clinics of YNHH, (b) inpatient admissions at Lake Regional Hospital (LRH) in Osage Beach, MO, (c) inpatient admissions at Memorial Hermann Southeast Hospital in Houston, TX, (d) outpatient visits and inpatient admissions at Methodist Cardiology Clinic in San Antonio, TX. In addition, we validated our approach in the prospective cohort from Brazil, the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil),[19] with protocolized ECG and echocardiogram in study participants.

Inclusion and exclusion criteria for external validation sets were similar to the internal YNHH dataset. Patients were limited to those having a 12-lead ECG within 15 days of a TTE with reported LVEF. For patients with more than one TTE in this interval, the LVEF from the nearest TTE was used for analysis.

At Cedars Sinai, all index ECG images from consecutive patients undergoing outpatient visits between, January through March 2019, representing 879 individuals, including 99 with $LVEF < 40\%$, were included. These analyses were performed in a fully federated and blinded fashion without access to any of the ECG data to the algorithm's developers.

For the other clinical validation sites, a stratified convenience sample enriched for low LVEF was drawn. This was done to evaluate the broad use in a clinical setting by practicing clinicians without access to a research dataset. Our preliminary assessment of LV systolic

dysfunction prevalence in outpatient and inpatient settings were 10% and 20%, respectively. We

sought to achieve twice this prevalence in our external validation data in these sites to ensure our

performance was not driven by patients with preserved LVEF and that the model could detect

those with LV systolic dysfunction. Specifically, a 1:4 ratio of ECGs corresponding to LVEF <

40% and ≥ 40% was sought at three of the four sites (YNHH, Memorial Hermann Southeast

Hospital, and Methodist Cardiology Clinic). At the fourth site, LRH, a 1:2 ratio was requested to

better measure the model's discriminative ability in an inpatient-only setting.

In addition to the clinical validation studies, where concurrent ECG and echocardiogram

are always clinically indicated, imposing a selection of the population, we evaluated our model

in the ELSA-Brasil study, a community-based prospective cohort in Brazil that obtained ECG

and echocardiography from participants on the enrollment visit between 2008-2010. This set

included data from 2,577 individuals, including 30 from individuals with LVEF < 40%.

Before validation, patient identifiers, ECG measurements, and reported diagnoses were

removed from all ECG images. The differences in ECG layouts and the procedures for validation

are described in further detail in the **Online Supplement**. Deidentified samples of ECG images

are presented in **Figure S5** (Cedars Sinai Medical Center ), **Figure S6** (YNHH and LRH),

**Figure S7** (Memorial Hermann Southeast Hospital), and **Figure S8** (Methodist Cardiology

Clinic), and images are available from the authors upon request.

**Localization of Model Predictive Cues**

We used Gradient-weighted Class Activation Mapping (Grad-CAM) to highlight which portions

of an image were important for the prediction of LVEF < 40%.[20] We calculated the gradients on

the final stack of filters in our EfficientNet-B3 model for each prediction and performed a global

average pooling of the gradients in each filter, emphasizing those that contributed to a prediction.

We then multiplied these filters by their importance weights and combined them across filters to

generate Grad-CAM heatmaps, which we overlayed on the original ECG images. We averaged

class activation maps among 100 positive cases with the most confident model predictions for

LVEF < 40% across ECG formats to determine the most important image areas for the prediction

of low LVEF. We took an arithmetic mean across the heatmaps for a given image format, and

overlayed this average heatmap across a representative ECG to understand it in context. The

activation map, a 10x10 array was upsampled to the original image size using the bilinear

interpolation built into TensorFlow v 2.8.0. We also evaluated the Grad-CAM for individual

ECGs to evaluate the consistency of the information on individual examples.

**Statistical Analysis**

Categorical variables were presented as frequency and percentages, and continuous variables as

means and standard deviations or median and interquartile range, as appropriate. Model

performance was evaluated in the held-out test set and external ECG image datasets. We used

area under the receiver operator characteristic (AUROC) to measure model discrimination. The

cut-off for binary prediction of LV systolic dysfunction was set at 0.10 for all internal and

external validations, based on the threshold that achieved a sensitivity of over 90% in the internal

validation set. We also assessed area under precision recall curve (AUPRC), sensitivity,

specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic odds

ratio. 95% CIs for AUROC and AUPRC were calculated using DeLong's algorithm and

bootstrapping with 1000 variations for each estimate, respectively.[21,22] Model performance was

assessed across demographic subgroups and ECG outlines, as described above. We conducted

further sensitivity analyses of model performance across ECG calibrations, PR intervals, and after

excluding paced rhythms, conduction disorders, atrial fibrillation, and atrial flutter. Moreover, we

assessed the association of the model's predicted probability of LV systolic dysfunction across

LVEF categories.

Next, we evaluated the future development of LV systolic dysfunction in time-to-event

models using a Cox proportional hazards model. In this analysis, we took the first temporal ECG

from the patients in the held-out test set, and then modeled the first development of LVEF < 40%

across the groups of patients who screened positive but did not have concurrent LV systolic

dysfunction (false positives), and those that screened negative (true negative) from this first ECG,

with censored at death or end of study period in June 2021. Additionally, we computed an

adjusted hazard ratio that accounted for differences in age, sex, and baseline LVEF at the time of

index screening for visualization of survival trends. Analytic packages used in model

development and statistical analysis are reported in **Table S1**. All model development and

statistical analyses were performed using Python 3.9.5 and the level of significance was set at an

alpha of 0.05.

**RESULTS**

**Study Population**

Out of the 2,135,846 ECGs obtained between 2015 to 2021, 440,072 were from patients who had

TTEs within 15 days of obtaining the ECG. Overall, 433,027 had a complete ECG recording,

representing 10 seconds of continuous recordings across all 12 leads. These ECGs were drawn

from 116,210 unique patients and were split into train, validation, and test sets at a patient level

(**Figure S1**).

A total of 116,210 individuals with 385,601 ECGs constituted the study population,

representing those included in the train, validation, test sets. Individuals whose ECGs were used

for model development had a median age of 68 years (IQR 56, 78) at the time of ECG recording,

and 59,282 (51.0%) were women. Overall, 75,928 (65.3%) were non-Hispanic white, 14,000

(12.0%) non-Hispanic Black, 9,349 (8.0%) Hispanic, and 16,843 (14.5%) were from other races.

A total of 56,895 (14.8%) ECGs had a corresponding echocardiogram with an LVEF below

40%, 36,669 (9.5%) had an LVEF greater than or equal to 40% but less than 50%, and 292,037

(75.7%) had LVEF 50% or greater (**Table S2**).

**Detection of LV Systolic Dysfunction**

The model's AUROC for detecting LVEF < 40% on the held-out test set composed of standard

images was 0.91 and its AUPRC was 0.55 (**Figure 2**). A probability threshold for predicting

LVEF < 40% was chosen based on a sensitivity of 0.90 or higher in the validation subset. With

this threshold, the model had sensitivity and specificity of 0.89 and 0.77 in the held-out test set,

and PPV and NPV of 0.26 and 0.99, respectively. Overall, an ECG suggestive of LV systolic

dysfunction portended over 27-fold higher odds (OR 27.5, 95% CI, 22.3 – 33.9) of LV systolic

dysfunction on TTE (**Table 1**). The model's performance was comparable across subgroups of

age, sex, and race (**Table 1** and **Figure 2**). Moreover, across successive deciles of the model

predicted probabilities, the proportion of individuals with LV systolic dysfunction increased,

while the mean LVEF decreased (**Figure S9**).

**Model Performance Across ECG Formats and Calibrations**

The model performance was comparable across the four original layouts of ECG images in the

held-out set with AUROC of 0.91 in detecting concurrent LV systolic dysfunction (**Table S3**).

The model had a sensitivity of 0.89 and a positive prediction conferred 26- to 27-fold higher

odds of LV systolic dysfunction on the standard and the three variations of the data. In sensitivity

analyses, the model demonstrated similar performance in detecting LV systolic dysfunction from

novel ECG formats that were not encountered before, with AUROC between 0.88-0.91 (**Table**

**S4)**.

The model performance was also consistent across ECG calibrations with an AUROC

between 0.88 and 0.91 on ECG calibrations of 5, 10, and 20 mm/mV and AUROC 0.908 (0.899

– 0.918) and AUPRC of 0.538 (0.503 – 0.573) with mixed calibrations in the held-out test set.

The mixed calibration was generated with a random sample of 5 mm/mV and 20 mm/mV

calibrations from the highest and lowest quartiles of voltages, respectively, in lead I (together

representing 25% of the sample from the test set), along with 10 mm/mV (remaining 75% of test

set) (**Table S5**). Further sensitivity analyses demonstrated consistent model performance on

ECGs (a) without prolonged PR interval (AUROC 0.920 and AUPRC 0.537, **Table S6**), (b)

without paced rhythms (AUROC 0.908, AUPRC 0.519, **Table S7**), and (c) without atrial

fibrillation, atrial flutter, and conduction disorders (AUROC 0.919, AUPRC 0.536, **Table S8**).

Model performance was also consistent across subsets on the held-out test set based on the

timing of the ECG relative to the echocardiogram (**Table S9**).

**LV Systolic Dysfunction in Model-predicted False Positives**

Of the 10,666 ECGs in the held-out test set with an associated LVEF ≥ 40% on a proximate

echocardiogram, the model classified 2,469 (23.1%) as "false positives", and 8,197 (76.9%) as

true negatives. In further evaluation of false positives, 562 (22.8% of false positives) had

evidence of mild LV systolic dysfunction with LVEF between 40-50% on concurrent

echocardiography.

In this group of individuals, 4,046 patients had at least one follow-up TTE, including

1,125 (27.8%) false positives and 2,921 (72.2%) true negatives on the initial index screen. There

were 2,665 and 6,083 echocardiograms in the false positive and true negative populations during

the follow-up, with the longest follow-up of 6.1 years. Overall, 264 (23.5%) patients with model-

predicted positive screen and 199 (6.8%) with negative screen developed new LVEF < 40% over

the median follow-up of 3.2 years (IQR 1.8-4.4 years, **Figure 3**). This represented a 3.9-fold

higher risk of incident low LVEF based on having a positive screening result (HR 3.9, 95% CI

3.3-4.7). After adjustment for age, sex, and LVEF at the time of screening, patients with positive

screen had a 2.3-fold higher risk of incident low LVEF (Adjusted HR 2.3, 95% CI 1.9-2.8).

**Localization of Predictive Cues for LV Systolic Dysfunction**

Class activation heatmaps of the 100 positive cases with the most confident model predictions

for reduced LVEF prediction across four ECG layouts are presented in **Figure 4**. For all four

formats of images, the region corresponding to leads V2 and V3 were the most important areas

for prediction of reduced LVEF. Representative images of Grad-CAM analysis in sampled

individuals with positive and negative screens in the held-out test set, and non-synthetic ECG

images in validation sites are presented in **Figures S10** and **S11**, respectively.

**External Validation**

The validation performance of the model was consistent and robust across each of the 6

validation datasets (**Figure 5**). The first validation set at Cedars Sinai Medical Center included

879 ECGs from consecutive patients who underwent outpatient echocardiography, including 99

(11%) individuals with LVEF < 40%. The model demonstrated an AUROC of 0.90 and an

AUPRC of 0.53 in this set. Second, a total of 147 ECG images drawn from YNHH outpatient

clinics were used for validation and included 27 images (18%) from patients with LVEF < 40%.

The model had an AUROC of 0.94 and AUPRC of 0.77 in validation on these images. The third

image dataset included ECG images from inpatient visits to the LRH. It included 100 ECG

images, with 43 images (43%) from patients with LVEF < 40%, with a model AUROC of 0.90

and AUPRC of 0.88. The fourth dataset from Memorial Hermann Southeast Hospital included 50

ECG images, 11 (22%) from patients with LVEF < 40%, with a model AUROC and AUPRC of

0.91 and 0.88 on these images, respectively. The fifth validation set contained 50 ECG images

from the Methodist Cardiology Clinic, which included 11 (20%) ECGs from patients with LVEF

< 40%, with model AUROC of 0.90 and AUPRC of 0.74.

The sixth set included 2,577 ECGs from prospectively enrolled individuals in the ELSA-

Brasil study, including 30 with LVEF < 40%. The model demonstrated an AUROC 0.95 and

AUPRC 0.45 on this set. The model performance on these 6 validation sets is outlined in **Table 2**

and **Table S10**.

**DISCUSSION**

We developed and externally validated an automated deep learning algorithm that accurately

identifies LV systolic dysfunction solely from ECG images. The algorithm has high

discrimination and sensitivity, representing characteristics ideal for a screening strategy. It is

robust to variations in the layouts of ECG waveforms and detects the location of ECG leads

across multiple formats with consistent accuracy, making it suitable for implementation in a

variety of settings. Moreover, the algorithm was developed and tested in a diverse population

with high performance in subgroups of age, sex, and race, and across geographically dispersed

academic and community health systems. It performed well in 6 external validation sites,

spanning both clinical settings as well as a prospective cohort study where protocolized

echocardiograms were performed concurrently with ECGs. An evaluation of the class-

discriminating signals localized it to the anteroseptal and anterior leads regardless of the ECG

layout, topologically corresponding to the left ventricle. Finally, among individuals who did not

have a concurrently recorded low LVEF, a positive ECG screen was associated with a 3.9-fold

increased risk of developing LV systolic dysfunction in the future compared with those with

negative screen, which was significant after adjustment for age, sex, and baseline LVEF.

Therefore, an ECG image-based approach can represent a screening as well as predictive strategy

for LV systolic dysfunction, particularly in low-resource settings.

Image-based analysis of ECGs through deep learning represents a novel application of AI

to improve clinical care. Convolutional neural networks have previously been designed to detect

low LVEF from ECG signals.[10,11] Although reliance of signal-based models on voltage data is

not computationally limited, their use in both retrospective and prospective settings requires

access to a signal repository where the ECG data architecture varies by ECG device vendors.

Moreover, data are often not stored beyond generating printed ECG images, particularly in

remote settings.[23] Furthermore, widespread adoption of signal-based models is limited by the

implementation barriers requiring health system-wide investments to incorporate them into

clinical workflow, something that may not be available or cost-effective in low-resource settings

and, to date, is not widely available in higher resource setting such as the US. The algorithm

reported in this study overcomes these limitations by making detection of LV systolic

dysfunction from ECGs interoperable across acquisition formats and directly available to

clinicians who only have access to ECG images. Since scanned ECG images are the most

common format of storage and use of electrocardiograms, untrained operators can implement

large scale screening through chart review or automated applications to image repositories – a

lower resource task than optimizing tools for different machines.

The use of ECG images in our model overcomes the implementation challenges arising

from black box algorithms. The origin of risk-discriminative signals in precordial leads of ECG

images suggests a left ventricular origin of the predictive signals. Moreover, the consistent

observation of these predictive signals in the anteroseptal and anterior leads, regardless of the

lead location on printed images, also serves as a control for the model predictions. Despite

localizing the class-discriminative signals in the image to the left ventricle, heatmap analysis

may not necessarily capture all the model predictive features, such as the duration of ECG

segments, intervals, or ECG waveform morphologies which might have been used in model

predictions. However, visual representations that are consistent with clinical knowledge could

explain parts of the model prediction process and address the hesitancy in uptake of these tools in

clinical practice.[24]

An important finding was the significantly increased risk of incident LV systolic

dysfunction among patients with model-predicted positive screen but LVEF ≥ 40% on

concurrent echocardiography. These findings demonstrate an electrocardiographic signature that

may precede the development of echocardiographic evidence of LV systolic dysfunction. This

was previously reported in signal-based models,[10] further suggesting that the detection of LV

systolic dysfunction on ECG images represents a similar underlying pathophysiological process.

These observations suggest a potential role for AI-based ECG models in risk stratification for

future development of cardiovascular disease.[25]

Our study has certain limitations that merit consideration. First, we developed this model

among patients with both ECGs and echocardiograms. Therefore, the training population

selected likely had a clinical indication for echocardiography, differing from the broader real-

world use of the algorithm for screening tests for LV systolic dysfunction among those without

any clinical disease. The excellent performance of our algorithm across demographic subgroups

and the validation population would suggest robustness and generalizability of the effects though

prospective assessments in the intended screening setting are warranted. Second, the model

performance may vary by degree of LV systolic dysfunction. Though we chose an LVEF

threshold of 40% due to its therapeutic implications, such as an indication for disease-modifying

guideline-directed medical therapies,[4] the model identifies individuals with mild dysfunction.

This may highlight a shared signature of LV systolic dysfunction among those with LVEF<40%,

and with LVEF of 40-50%, but could also represent the lack of precision of LVEF measurement

by echocardiography relative to more precise approaches, such as magnetic resonance

imaging.[26,27] Third, while we incorporated four ECG formats during its development and

demonstrated that the model had a consistent performance on a range of commonly used and

novel layouts that were not included in the development, we cannot ascertain whether it

maintains performance on every novel format. Fourth, while the model development pursues

preprocessing the ECG signal for plotting images, these represent standard processes performed

before ECG images are generated and/or printed by ECG machines. Therefore, any other

processing of images is not required for real-world application, as demonstrated in the

application of the model to the external validation sets.

**CONCLUSIONS**

We developed an automated algorithm to detect LV systolic dysfunction from ECG images,

demonstrating a robust performance across subgroups of patient demographics, ECG formats and

calibrations, and clinical practice settings. Given the ubiquitous availability of ECG images, this

approach represents a strategy for automated screening of LV systolic dysfunction, especially in

resource-limited settings.

**ACKNOWLEDGEMENTS**

**Author contributions:** RK conceived the study and accessed the data. VS and RK developed the

model. VS, AAN, LD, AK, and RK pursued the statistical analysis. VS and AAN drafted the

manuscript. All authors provided feedback regarding the study design and made critical

contributions to writing of the manuscript. RK supervised the study, procured funding, and is the

guarantor.

**Funding:** This study was supported by research funding awarded to Dr. Khera by the Yale School

of Medicine and grant support from the National Heart, Lung, and Blood Institute of the National

Institutes of Health under the award K23HL153775. The funders had no role in the design and

conduct of the study; collection, management, analysis, and interpretation of the data; preparation,

review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Competing Interests:** Dr. Mortazavi reported receiving grants from the National Institute of

Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food

and Drug Administration, and the US Department of Defense Advanced Research Projects

Agency outside the submitted work; in addition, Dr. Mortazavi has a pending patent on

predictive models using electronic health records (US20180315507A1). Antonio H. Ribeiro is

funded by *Kjell och Märta Beijer Foundation*. Dr. Krumholz works under contract with the

Centers for Medicare & Medicaid Services to support quality measurement programs, was a

recipient of a research grant from Johnson & Johnson, through Yale University, to support

clinical trial data sharing; was a recipient of a research agreement, through Yale University, from

the Shenzhen Center for Health Information for work to advance intelligent disease prevention

and health promotion; collaborates with the National Center for Cardiovascular Diseases in

Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi

clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect

IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx

litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the

IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element

Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is

the co-founder of Hugo Health, a personal health information platform, and co-founder of

Refactor Health, a healthcare AI-augmented data management company. Dr Ribeiro is supported

in part by CNPq (465518/2014-1, 310790/2021-2 and 409604/2022-4) and by FAPEMIG (PPM-

00428-17, RED-00081-16 and PPE-00030-21). Mr. Sangha and Dr. Khera are the coinventors of

U.S. Provisional Patent Application No. 63/346,610, "Articles and methods for format

independent detection of hidden cardiovascular disease from printed electrocardiographic images

using deep learning". Dr. Khera is also a founder of Evidence2Health, a precision health

platform to improve evidence-based care.

**Model Availability:** The model is available in an online format for research use at

https://www.cards-lab.org/ecgvision-lv

**REFERENCES**

1.      Wang, T. J. *et al.* Natural history of asymptomatic left ventricular systolic dysfunction in
the community. *Circulation* **108**, 977–982 (2003).
2.      Srivastava, P. K. *et al.* Heart Failure Hospitalization and Guideline-Directed Prescribing
Patterns Among Heart Failure With Reduced Ejection Fraction Patients. *JACC Heart Fail* **9**, 28–
38 (2021).
3.      Wolfe, N. K., Mitchell, J. D. & Brown, D. L. The independent reduction in mortality
associated with guideline-directed medical therapy in patients with coronary artery disease and
heart failure with reduced ejection fraction. *Eur Heart J Qual Care Clin Outcomes* **7**, 416–421
(2021).
4.      Heidenreich, P. A. *et al.* 2022 AHA/ACC/HFSA Guideline for the Management of Heart
Failure: A Report of the American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines. *Circulation* 101161CIR0000000000001063 (2022).

5.      Wang, T. J., Levy, D., Benjamin, E. J. & Vasan, R. S. The epidemiology of
"asymptomatic" left ventricular systolic dysfunction: implications for screening. *Ann. Intern.*
*Med.* **138**, 907–916 (2003).
6.      Vasan, R. S. *et al.* Plasma natriuretic peptides for community screening for left
ventricular hypertrophy and systolic dysfunction: the Framingham heart study. *JAMA* **288**, 1252–
1259 (2002).
7.      McDonagh, T. A., McDonald, K. & Maisel, A. S. Screening for asymptomatic left
ventricular dysfunction using B-type natriuretic Peptide. *Congest. Heart Fail.* **14**, 5–8 (2008).
8.      Galasko, G. I., Barnes, S. C., Collinson, P., Lahiri, A. & Senior, R. What is the most cost-
effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the
electrocardiogram, hand-held echocardiography, traditional echocardiography, or their
combination? *Eur Heart J* **27**, 193–200 (2006).
9.      Atherton, J. J. Screening for left ventricular systolic dysfunction: is imaging a solution?
*JACC Cardiovasc Imaging* **3**, 421–428 (2010).
10.     Attia, Z. I. *et al.* Screening for cardiac contractile dysfunction using an artificial
intelligence-enabled electrocardiogram. *Nat Med* **25**, 70–74 (2019).
11.     Vaid, A. *et al.* Using Deep-Learning Algorithms to Simultaneously Identify Right and
Left Ventricular Dysfunction From the Electrocardiogram. *JACC Cardiovasc Imaging* **15**, 395–
410 (2022).
12.     Yao, X. *et al.* Artificial intelligence-enabled electrocardiograms for identification of
patients with low ejection fraction: a pragmatic, randomized clinical trial. *Nat Med* **27**, 815–819
(2021).
13.     Stamenov, D., Gusev, M. & Armenski, G. *Interoperability of ECG standards*. (IEEE,
2018).
14.     Sangha, V. *et al.* Automated multilabel diagnosis on electrocardiographic images and
signals. *Nat Commun* **13**, 1583 (2022).
15.     He, J. *et al.* The practical implementation of artificial intelligence technologies in
medicine. *Nat Med* **25**, 30–36 (2019).
16.     ECG Plot Python Library. Accessed at https://pypi.org/project/ecg-plot/ on May 25,
2022.
17.     Cui, Y., Jia, M., Lin, T.-Y., Song, Y. & Belongie, S. Class-Balanced Loss Based on
Effective Number of Samples. arXiv:1901.05555 (2019).
18.     Mingxing Tan and Quoc V Le. EfficientNet: Rethinking model scaling for convolutional
neural networks. *International Conference on Machine Learning, 2019*.
19.     Aquino, E. M. L. *et al.* Brazilian Longitudinal Study of Adult Health (ELSA-Brasil):
objectives and design. *Am. J. Epidemiol.* **175**, 315–324 (2012).
20.     Selvaraju, R. R. *et al.* Grad-CAM: Visual Explanations from Deep Networks via
Gradient-based Localization. *2017 Ieee International Conference on Computer Vision (Iccv)*
618–626 (2017).
21.     DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two
or more correlated receiver operating characteristic curves: a nonparametric approach.
*Biometrics* **44**, 837–845 (1988).
22.     Sun, X. & Xu, W. Fast implementation of DeLong's algorithm for comparing the areas
under correlated receiver operating characteristic curves. *IEEE Signal Process. Lett.* **21**, 1389–
1393 (2014).

23.     Siontis, K. C., Noseworthy, P. A., Attia, Z. I. & Friedman, P. A. Artificial intelligence-
enhanced electrocardiography in cardiovascular disease management. *Nat Rev Cardiol* **18**, 465–
478 (2021).
24.     Quer, G., Arnaout, R., Henne, M. & Arnaout, R. Machine Learning and the Future of
Cardiovascular Care: JACC State-of-the-Art Review. *J Am Coll Cardiol* **77**, 300–313 (2021).
25.     Maurovich-Horvat, P. Current trends in the use of machine learning for diagnostics
and/or risk stratification in cardiovascular disease. *Cardiovasc Res* **117**, e67–e69 (2021).
26.     Pellikka, P. A. *et al.* Variability in Ejection Fraction Measured By Echocardiography,
Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in
Patients With Coronary Artery Disease and Left Ventricular Dysfunction. *JAMA Netw Open* **1**,
e181456 (2018).
27.     Jenkins, C. *et al.* Left ventricular volume measurement with echocardiography: a
comparison of left ventricular opacification, three-dimensional echocardiography, or both with
magnetic resonance imaging. *Eur Heart J* **30**, 98–106 (2009).
592

**Table 1. Performance of model on test images across demographic subgroups in the held-out test set.** Abbreviations: PPV, positive predictive value; NPV, negative predictive value; AUROC, area under receiver operating characteristic curve; AUPRC, area under precision recall curve; OR, odds ratio

| Labels | Number | PPV | NPV | Specificity | Sensitivity | AUROC | AUPRC |
|---|---|---|---|---|---|---|---|
| All | 11621 (100%) | 0.257 | 0.988 | 0.769 | 0.892 | 0.910 (0.901-0.919) | 0.545 (0.511 – 0.579) |
| Male | 5952 (51.2%) | 0.285 | 0.984 | 0.735 | 0.897 | 0.901 (0.889-0.914) | 0.583 (0.539 – 0.621) |
| Female | 5668 (48.8%) | 0.215 | 0.991 | 0.802 | 0.884 | 0.917 (0.903-0.932) | 0.470 (0.416 – 0.530) |
| ≥ 65 | 6550 (56.4%) | 0.252 | 0.985 | 0.717 | 0.896 | 0.892 (0.880-0.905) | 0.522 (0.480 – 0.561) |
| < 65 | 5068 (43.6%) | 0.266 | 0.991 | 0.833 | 0.886 | 0.931 (0.916-0.945) | 0.590 (0.534 – 0.655) |
| Hispanic | 942 (8.1%) | 0.253 | 0.992 | 0.802 | 0.908 | 0.926 (0.892-0.961) | 0.576 (0.453 – 0.696) |
| White | 7557 (65.0%) | 0.261 | 0.988 | 0.770 | 0.895 | 0.910 (0.898-0.921) | 0.537 (0.498 – 0.580) |
| Black | 1417 (12.2%) | 0.263 | 0.984 | 0.712 | 0.897 | 0.899 (0.872-0.925) | 0.590 (0.498 – 0.665) |
| Other | 1705 (14.7%) | 0.231 | 0.987 | 0.787 | 0.864 | 0.912 (0.887-0.937) | 0.532 (0.437 – 0.625) |

 * Gender information was not available for 1 patient and age was not available for 3 patient of the total 11,621 patients in the held-out test set

**Table 2. Performance of model on external validation datasets.** Abbreviations: PPV, positive predictive value; NPV, negative predictive value; AUROC, area under receiver operating characteristic curve; AUPRC, area under precision recall curve; ELSA-Brasil, Estudo Longitudinal de Saúde do Adulto (The Brazilian Longitudinal Study of Adult Health)

| Site | PPV | NPV | Specificity | Sensitivity | AUROC | AUPRC |
|------|-----|-----|-------------|-------------|-------|-------|
| Cedars Sinai Medical Center | 0.326 | 0.979 | 0.772 | 0.869 | 0.902 (0.877 – 0.926) | 0.533 (0.432 – 0.640) |
| Outpatient Clinics of YNHH | 0.338 | 1.000 | 0.558 | 1.000 | 0.946 (0.910 - 0.982) | 0.775 (0.605 – 0.916) |
| LRH | 0.538 | 0.955 | 0.368 | 0.977 | 0.901 (0.843 - 0.959) | 0.889 (0.810 – 0.946) |
| Memorial Hermann Southeast Hospital | 0.385 | 0.958 | 0.590 | 0.909 | 0.918 (0.790 - 1.000) | 0.888 (0.699 – 1.000) |
| Methodist Cardiology Clinic | 0.458 | 1.000 | 0.667 | 1.000 | 0.902 (0.816 - 0.989) | 0.738 (0.470 – 0.928) |
| ELSA-Brasil | 0.256 | 0.996 | 0.976 | 0.700 | 0.949 (0.915 – 0.983) | 0.449 (0.290 – 0.651) |

**Figure 1. Study Outline A) Data processing, B) Model training, and C) Model validation.**
Abbreviations: ECG, electrocardiogram; EF, ejection fraction; FC, fully connected layers; Grad-CAM, gradient-weighted class activation mapping; CT, Connecticut; ELSA-Brasil, Estudo Longitudinal de Saúde do Adulto (The Brazilian Longitudinal Study of Adult Health); MO, Missouri; TX, Texas.

## A. Data Processing

**Image Transformation**

Image Resizing

Standard  Standard Shuffled

Alternate  Two Rhythm

Echocardiogram with EF + ECG data (2015-2021)

## B. Model Training

Clinical Labels & Gender → FC → Clinical Labels & Gender

Transfer Learning

Four Transformed Image Formats

Frozen Layers · Global Average Pooling · Batch Norm · FC → EF < 40%

Probability of Low EF

EF < 40% ← FC · Batch Norm · Global Average Pooling ← Four Transformed Image Formats

Grad-CAM

Grad-CAM Heatmap

Pre-training     Frozen Layers     Convolutional Blocks
Transfer Learning 1     Transfer Learning 2

## C. Model Validation

**INTERNAL VALIDATION**

11,621 Held-Out ECGs x4
955 Low EF Patients
2015-2021

Standard Format     Standard Shuffled Format

Alternate Format     Rhythm Format

**CONSECUTIVE SAMPLE**

Cedars Sinai Medical Center, Los Angeles, CA

879 Real-World ECGs
99 Low EF Patients
2019

**PROTOCOLIZED ECG & TTE**

ELSA-Brasil, (Longitudinal Study of Adult Health), Brazil

2577 Real-World ECGs
30 Low EF Patients
2008-2010

**STRATIFIED CONVENIENCE SAMPLE**

Outpatient Clinics, Yale-New Haven Hospital, New Haven, CT

147 Real-World ECGs
27 Low EF Patients
2022

Lake Regional Hospital, Osage Beach, MO

100 Real-World ECGs
43 Low EF Patients
2022

Memorial Hermann Southeast Hospital, Houston, TX

50 Real-World ECGs
11 Low EF Patients
2022

Methodist Cardiology Clinic, San Antonio, TX

50 Real-World ECGs
11 Low EF Patients
2022

Detection of Low EF + Prediction of Future Low EF

Detection of Low EF

*We pursued a transfer learning strategy in developing the current model from our previous algorithm which was originally trained to detect cardiac rhythm disorders and the hidden label of gender from ECG images. The transfer learning was used as initialization weights for the EfficientNet B3 convolutional neural network being trained to detect LV systolic dysfunction. Other than the weights, clinical and gender labels were not input to the current model.

**Figure 2. Model Performance Measures A) Receiver-Operating and B) Precision-Recall Curves on images in held-out test set C) Diagnostic Odds Ratios across age, gender, and race subgroups on standard format images in the held-out test set.** Abbreviations: AUROC, area under receiver-operating characteristic curve; AUPRC, area under precision-recall curve.

**Figure 3. Cumulative hazard curves for incident LV systolic dysfunction in model-predicted positive and negative screens amongst the members of the held-out test set with LVEF ≥ 40% and at least one follow-up measurement.**

**Figure 4. Gradient-weighted Class Activation Mapping (Grad-CAMs) across ECG formats. A) Standard format B) Two rhythm leads C) Standard shuffled format D) Alternate format.** The heatmaps represent averages of the 100 positive cases with the most confident model predictions for LVEF < 40%.

**Figure 5. Receiver-Operating Curves for external validation sites.** Abbreviations: AUROC, area under receiver-operating characteristic curve; EF, Ejection fraction; LRH, Lake Regional Hospital; YNHH, Yale New Haven Hospital